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Collections of tumour cell lines continue to represent val-
uable resources in cancer research. However, cell banks
rarely provide detailed immunological characterisation of
the lines that they offer. To redress this omission, ESTDAB
was founded as an EU infrastructures project, (see http://
www.medizin.uni-tuebingen.de/estdab). It now provides
the world's largest collection of melanoma cell lines, and
is the only cell bank to offer the researcher the ability to
seek cells with combinations of immunologically-relevant
characteristics (go to http://www.ebi.ac.uk/ipd/estdab/
index.html). These include HLA class I and II high resolu-
tion typing, HLA expression patterns, tumour antigen
expression, cytokine secretion, adhesion molecule expres-
sion, apoptosis resistance, surface glycosylation patterns
and other parameters. These lines are available to bona
fide investigators for research purposes. Examples of stud-
ies being performed using this resource are elution of HLA
class I- and II-bound peptides to identify novel
melanoma-associated antigens, assessment of mecha-
nisms of MHC antigen loss, defects in antigen processing
pathways, secretion of suppressive factors, influence of
the culture environment and presence of other cell types
on cancer cell characteristics, and activity of glycosyltrans-
ferases creating tumour-type glycan structures. Together
with the EU project OISTER (Outcome and Impact of Spe-
cific Treatment in European Research on Melanoma, coor-
dinated by D. Schadendorf), we are continuously
collecting new cell lines generated from patients entered
into immunotherapy trials. The appropriateness of these
lines for monitoring purposes is being established. Here,
we report studies on four melanoma cell lines which were
chosen for propagation and elution of HLA-bound pep-
tides by "acid-stripping" from the surface of viable cells.
FACS analysis of HLA expression before and after this pro-
cedure confirmed that HLA class I expression decreased
after peptide elution. The peptide content of the eluted
samples was established by mass spectrometric analysis,
and the eluates screened for immunogenicity in vitro on T
cells of normal donors selected for sharing at least one
HLA-I allele with the melanoma cell line. T cells were cul-
tured in the presence of different cytokines and titrated
amounts of eluate, using either autologous antigen-pre-
senting cells, APC (eluate-pulsed irradiated PBMC, den-
dritic cells generated from the same donor, or HLA-
matched B-cells). After several rounds of restimulation, T
cell lines recognising eluate-pulsed autologous APC were
obtained. Investigation of their exact antigenic specificity
is now in progress. For studies on MHC class II-bound
peptides, monoclonal antibodies were used to isolate
HLA-DR, DQ and DP molecules from lysates of at least
1010 tumor cells. From these, HLA class II-bound peptides
were eluted at low pH and fractionated by HPLC. After
screening T cell reactivity, positive fractions were
sequenced by MALDI-TOF in order to determine potential
tumor-specific antigens and identify related T cell
epitopes. Potentially immunogenic candidates thus far
identified include an HLA-DR-restricted sequence derived
from a possibly mutated stress protein (grp78) NVMRI-
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INEPTAAAIA. Several non-mutated peptides from over-
expressed molecules did not show evidence of
immunogenicity in vitro. The availability of the ESTDAB
collection will facilitate immunological investigation of in
vitro human melanoma models.
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